Israel · Delayed Price · Currency is ILS · Price in ILA BioLineRx Earnings Call Transcripts
Fiscal Year 2025
-
GLIX1 advanced to clinical trials for glioblastoma with strong investigator enthusiasm and orphan drug status, while revenues fell sharply due to lower milestone payments. Cash reserves are sufficient into 2027, and a legal dispute was resolved favorably, removing financial risk.
-
A new JV was formed to develop GLIX1 for glioblastoma, with a phase I/II-A trial starting in Q1 2026 and strong patent protection secured. Q3 2025 saw $0.4M in revenue, a $1M net loss, and a $25.2M cash position, supporting operations into 2027.
-
A joint venture was formed to develop GLYCS1, a novel oral small molecule targeting DNA repair in glioblastoma and other cancers. Preclinical data show strong efficacy and safety, with a phase 1-2A trial set for 2026. The asset is protected by robust IP and targets a large, underserved market.
-
Q2 2025 saw $0.3M in royalty revenue and a $3.9M net loss, with a strong cash position extending runway into 2027. Pipeline expansion is prioritized, with a transaction for early-stage oncology or rare disease assets targeted this year.
-
Effexta outlicensing to Aramid drove a shift to royalty-based revenue, with Q1 2025 net income of $5.1 million and a strong cash position. Streamlined operations cut annual cash burn by over 70%, while promising clinical data in pancreatic cancer and sickle cell disease support future growth.
Fiscal Year 2024
-
Signed a major licensing deal for APHEXDA, securing $10M upfront, $87M in milestones, and 18–23% royalties, plus a $9M equity investment, enabling debt repayment and a >70% cost reduction. Q3 revenue rose to $4.9M, with APHEXDA gaining 10% U.S. market share.
-
Signed a major licensing deal for APHEXDA, reducing costs and refocusing on drug development. Q3 revenue reached $4.9M, with a significant drop in net loss and cash runway extended into 2026. APHEXDA achieved strong market traction, and new clinical assets are targeted for 2025 and 2026.
-
Q2 2024 saw strong APHEXDA adoption, surpassing formulary placement goals and doubling sales from Q1. Revenue reached $5.4M, with net income of $0.5M, and cash reserves of $40.1M expected to fund operations into 2025. Multiple clinical milestones and expansion efforts are underway.